NEW YORK (GenomeWeb News) - Bio-Rad said today it plans to buy reagent and screening tool-maker DiaMed Holding for around 477 million Swiss francs ($390 million).
The companies signed a definitive agreement under which Bio-Rad would buy 77.7 percent of DiaMed’s outstanding shares, after which Bio-Rad plans to conduct a tender offer buy nearly 13 percent of the remaining outstanding shares. The remaining 9.6 percent of DiaMed’s shares are treasury shares.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.